SCHEMBL2045019

SCHEMBL2045019

C[C@]12CCC(=O)C=C1C=C[C@@H]1[C@@H]2CC[C@]2(C)C(O)CC[C@@H]12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.73
PGR P06401 5/20 0.73
AR P10275 4/20 0.73
ALDH1A1 P00352 1/20 0.73
CYP2C19 P33261 1/20 0.73
CHRM1 P11229 1/20 0.73
TBXA2R P21731 1/20 0.73
ADRA1A P35348 1/20 0.73
CYP19A1 P11511 7/20 0.67
NR3C1 P04150 4/20 0.61
CHRM2 P08172 1/20 0.61
OPRK1 P41145 1/20 0.61
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
LMNA P02545 4/20 0.57
SHBG P04278 4/20 0.57
HSD17B10 Q99714 3/20 0.57
SERPINA6 P08185 2/20 0.57
TSHR P16473 2/20 0.57
SNCA P37840 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3364701 1.00 CYP3A4 (0.73) CYP3A4PGRARALDH1A1CYP2C19
SCHEMBL2045021 1.00 CYP3A4 (0.73) CYP3A4PGRARALDH1A1CYP2C19
SCHEMBL23563828 0.86 PGR (0.71) CYP3A4PGRARALDH1A1CYP2C19
SCHEMBL18767708 0.86 PGR (0.71) CYP3A4PGRARALDH1A1CYP2C19
SCHEMBL11429970 0.86 CYP19A1 (0.57) CYP3A4PGRARALDH1A1CYP2C19
Dydrogesterone SCHEMBL11512798 0.85 CYP3A4 (1.00) CYP3A4PGRARALDH1A1CYP2C19
Dydrogesterone SCHEMBL18814051 0.85 CYP3A4 (1.00) CYP3A4PGRARALDH1A1CYP2C19
Dydrogesterone SCHEMBL23383832 0.85 CYP3A4 (1.00) CYP3A4PGRARALDH1A1CYP2C19
Dydrogesterone SCHEMBL606817 0.85 CYP3A4 (1.00) CYP3A4PGRARALDH1A1CYP2C19
Dydrogesterone SCHEMBL606816 0.85 CYP3A4 (1.00) CYP3A4PGRARALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2660241-A2 C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 BioMarin Pharmaceutical Inc. (US) 2013-11-06 EP disclosed
US-20130252930-A1 CYP11B, CYP17, AND/OR CYP21 INHIBITORS BIOMARIN PHARMACEUTICAL INC. (CA) 2013-09-26 US disclosed
US-20130252930-A1 CYP11B, CYP17, AND/OR CYP21 INHIBITORS BIOMARIN PHARMACEUTICAL INC. (CA) 2013-09-26 US disclosed
EP-2512485-A1 NEW STEROID INHIBITORS OF PGP FOR USE FOR INHIBITING MULTIDRUG RESISTANCE Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2012-10-24 EP disclosed
WO-2012083112-A2 CYP11B, CYP17, AND/OR CYP21 INHIBITORS BIOMARIN PHARMACEUTICAL INC. (US) 2012-06-21 WO disclosed
WO-2011073419-A1 NEW STEROID INHIBITORS OF PGP FOR USE FOR INHIBITING MULTIDRUG RESISTANCE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252930-A1 CYP11B, CYP17, AND/OR CYP21 INHIBITORS CYP4A11, HSD17B11, CYP21A2 CYP3A4 44/4885PGR 207/4885AR 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.